Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.
A simple blood test for GFAP now reliably detects early Alzheimer's disease changes, offering patients a less invasive alternative to spinal fluid collection.
This biomarker validation study demonstrates that plasma GFAP — a simple blood test — surpasses CSF GFAP for detecting amyloid pathology and predicting clinical progression in early Alzheimer's disease. These findings advance the case for blood-based AD biomarkers as a less invasive alternative to lumbar puncture for diagnostic and prognostic stratification.
What the study was
- Study design
- Observational / biomarker validation study
- Population
- Patients in early Alzheimer's disease spectrum with amyloid pathology
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- The Journal of Prevention of Alzheimer's Disease
Why it surfaced
Blood-based AD biomarker validation is high clinical utility; plasma GFAP showing superiority to CSF GFAP has immediate practical implications for diagnostic workflows.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.